stockrow
Saturday 7 November 2026
Export LENZ’s income statement to Excel — free account
LENZ Therapeutics, Inc.
LENZ Healthcare Biotechnology
LENZ Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $19.1 million.
- Revenue
- −72.9%
- EPS
- −67.1%
- Free cash flow
- −147.2%
Quarter to September 2026, against a year earlier
3.47
0.46
+15.28%
Follow LENZ
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(33.63%) | (49.71%) | (59.21%) | (72.69%) | |
| (31.52%) | (46.01%) | (55.52%) | (66.72%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(29.18%) | (44.73%) | (58.05%) | (73.91%) | |
Average Days of Receivables |
0.00 | 5.96 | 7.51 | 26.96 | |
Free Cash Flow per Share |
(2.43) | (2.79) | (3.65) | (4.06) | |
Free Cash Flow |
(70.00) | (87.44) | (114.42) | (127.70) | |
Capital Expenditures |
(0.83) | (0.73) | (0.51) | (0.07) | |
| Other line items | |||||
Cash ROIC |
(12.14%) | (17.32%) | (26.05%) | (32.80%) | |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.85 | 0.90 | 0.53 | |
Inventory Turnover |
— | 0.00 | 0.00 | 0.91 | |
Average Days of Payables |
0.00 | 644.02 | 570.41 | 771.53 | |
Days of Inventory on Hand |
0.00 | 206.13 | 353.59 | 665.67 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 151.06% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 595.48% | 705.78% | 1,293.14% | |
Share Based Compensation of Revenue |
0.00% | 68.18% | 74.22% | 134.34% | |
Operating CF/Net income |
0.84 | 0.80 | 0.90 | 0.91 | |
Depreciation/Fixed assets |
0.24 | 0.33 | 0.45 | 0.68 | |
Capex/Depreciation |
(2.88) | (2.03) | (1.13) | (0.16) | |
Revenue per Share |
0.00 | 0.67 | 0.68 | 0.39 | |
Operating CF per Share |
(2.40) | (2.77) | (3.63) | (4.06) | |
Capex per Share |
(0.03) | (0.02) | (0.02) | 0.00 | |
Capex to Sales |
0.00 | 0.04 | 0.02 | 0.01 |
Columns are period end dates · fundamentals updated 5 Nov 2026